Literature DB >> 24424456

On the TRAIL to overcome BRAF-inhibitor resistance.

Peter Geserick1, Meenhard Herlyn2, Martin Leverkus3.   

Abstract

BRAF inhibition has been an instant, although short-lasting, success in BRAF-mutated melanoma treatment. Novel data by Berger et al. now suggest that BRAF-inhibitor-mediated "priming to death" facilitates tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis. We give an overview about the importance of the crosstalk of extrinsic and mitochondrial apoptotic signaling and propose other combination therapies that may prevent or overcome secondary resistance in melanoma.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24424456     DOI： 10.1038/jid.2013.348

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


  16 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

3.  RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells.

Authors:  Anja Berger; Sandra-Annika Quast; Michael Plötz; Nicholas-Frederik Kuhn; Uwe Trefzer; Jürgen Eberle
Journal:  J Invest Dermatol       Date:  2013-08-16       Impact factor: 8.551

Review 4.  Signal transduction in human cutaneous melanoma and target drugs.

Authors:  Anatoly B Uzdensky; Svetlana V Demyanenko; Mikhail Y Bibov
Journal:  Curr Cancer Drug Targets       Date:  2013-10       Impact factor: 3.428

5.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.

Authors:  Alexander Roesch; Adina Vultur; Ivan Bogeski; Huan Wang; Katharina M Zimmermann; David Speicher; Christina Körbel; Matthias W Laschke; Phyllis A Gimotty; Stephan E Philipp; Elmar Krause; Sylvie Pätzold; Jessie Villanueva; Clemens Krepler; Mizuho Fukunaga-Kalabis; Markus Hoth; Boris C Bastian; Thomas Vogt; Meenhard Herlyn
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

6.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

7.  Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis.

Authors:  Hyungjin Kim; Ho-Chou Tu; Decheng Ren; Osamu Takeuchi; John R Jeffers; Gerard P Zambetti; James J-D Hsieh; Emily H-Y Cheng
Journal:  Mol Cell       Date:  2009-11-13       Impact factor: 17.970

8.  Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.

Authors:  P Geserick; C Drewniok; M Hupe; T L Haas; P Diessenbacher; M R Sprick; M P Schön; F Henkler; H Gollnick; H Walczak; M Leverkus
Journal:  Oncogene       Date:  2007-12-17       Impact factor: 9.867

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.

Authors:  Peter Geserick; Mike Hupe; Maryline Moulin; W Wei-Lynn Wong; Maria Feoktistova; Beate Kellert; Harald Gollnick; John Silke; Martin Leverkus
Journal:  J Cell Biol       Date:  2009-12-28       Impact factor: 10.539
View more
  6 in total

Review 1.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675

2.  Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

Authors:  G Grazia; C Vegetti; F Benigni; I Penna; V Perotti; E Tassi; I Bersani; G Nicolini; S Canevari; C Carlo-Stella; A M Gianni; R Mortarini; A Anichini
Journal:  Cell Death Dis       Date:  2014-10-02       Impact factor: 8.469

3.  Absence of RIPK3 predicts necroptosis resistance in malignant melanoma.

Authors:  P Geserick; J Wang; R Schilling; S Horn; P A Harris; J Bertin; P J Gough; M Feoktistova; M Leverkus
Journal:  Cell Death Dis       Date:  2015-09-10       Impact factor: 8.469

4.  Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF-κB inhibition.

Authors:  Abdelouahid El-Khattouti; Denis Selimovic; Matthias Hannig; Erin B Taylor; Zakaria Y Abd Elmageed; Sofie Y Hassan; Youssef Haikel; Emad Kandil; Martin Leverkus; Robert T Brodell; Mosaad Megahed; Mohamed Hassan
Journal:  J Cell Mol Med       Date:  2015-11-18       Impact factor: 5.310

5.  Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells.

Authors:  Mahiro Iizuka-Ohashi; Motoki Watanabe; Mamiko Sukeno; Mie Morita; Ngoc Thi Hong Hoang; Takahiro Kuchimaru; Shinae Kizaka-Kondoh; Yoshihiro Sowa; Koichi Sakaguchi; Tetsuya Taguchi; Toshiyuki Sakai
Journal:  Oncotarget       Date:  2018-04-13

6.  Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.

Authors:  Dan A Erkes; Weijia Cai; Ileine M Sanchez; Timothy J Purwin; Corey Rogers; Conroy O Field; Adam C Berger; Edward J Hartsough; Ulrich Rodeck; Emad S Alnemri; Andrew E Aplin
Journal:  Cancer Discov       Date:  2019-12-03       Impact factor: 38.272
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.